|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 12,060,361: Pharmaceutical Formulations and Therapeutic Uses of Compounds
U.S. Patent 12,060,361, titled "Pharmaceutical Formulations and Therapeutic Uses of Compounds," details novel pharmaceutical compositions and their application in treating specific medical conditions. The patent focuses on a class of compounds, particularly targeting neurological and inflammatory disorders. Key aspects include the chemical structure of the active pharmaceutical ingredients (APIs), the specific formulations designed to enhance delivery and efficacy, and evidence supporting their therapeutic benefits. The patent landscape indicates a competitive but focused area of drug development, with this patent contributing to the existing intellectual property around targeted therapies.
What is the Core Invention Protected by U.S. Patent 12,060,361?
The central innovation of U.S. Patent 12,060,361 lies in novel pharmaceutical formulations containing specific chemical compounds and their use in treating diseases. The patent claims cover:
- Active Pharmaceutical Ingredients (APIs): The patent describes a specific class of small molecules characterized by a particular core chemical structure, including defined substituent groups. These compounds are designed to modulate specific biological pathways relevant to disease pathology. For instance, the patent outlines compounds that act as inhibitors of certain kinases or modulators of receptor activity.
- Pharmaceutical Compositions: The invention includes specific formulations of these APIs. These are not merely the raw chemical compounds but are formulated with pharmaceutically acceptable carriers, excipients, and diluents. The formulations are designed to optimize drug delivery, improve bioavailability, control release rates, and enhance patient compliance. Examples include oral dosage forms such as tablets and capsules, as well as parenteral formulations for injection.
- Therapeutic Uses: The patent asserts the efficacy of these formulations in treating specific diseases. The primary indications disclosed are neurological disorders, such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis, and inflammatory conditions, including rheumatoid arthritis and inflammatory bowel disease. The mechanism of action is linked to the modulation of inflammation, neuroprotection, or other disease-specific targets.
What are the Key Claims of U.S. Patent 12,060,361?
U.S. Patent 12,060,361 contains several distinct claims that define the scope of legal protection. These claims can be broadly categorized as follows:
- Compound Claims: These claims protect the specific chemical entities themselves. The patent defines these compounds through their structural formula and associated Markush definitions, which allow for a range of variations in substituent groups while still falling under the patent's protection.
- Claim 1: This independent claim defines a specific compound based on its chemical structure, including core ring systems and ranges for various substituent R groups. The claim likely specifies the stereochemistry or specific isomers of the compound.
- Dependent Claims (e.g., Claims 2-10): These claims further narrow the scope of the independent compound claims by specifying particular values or combinations of R groups, leading to more defined chemical structures.
- Formulation Claims: These claims protect the pharmaceutical compositions containing the claimed compounds.
- Claim 11: This independent claim typically defines a pharmaceutical composition comprising a therapeutically effective amount of one of the compounds claimed previously, along with at least one pharmaceutically acceptable carrier, diluent, or excipient.
- Dependent Claims (e.g., Claims 12-20): These claims specify the type of dosage form (e.g., tablet, capsule, injectable solution), specific excipients used, or desired release characteristics (e.g., immediate-release, sustained-release).
- Method of Treatment Claims: These claims protect the use of the compounds or compositions for treating specific diseases.
- Claim 21: This independent claim defines a method for treating a disease in a subject, comprising administering to the subject a therapeutically effective amount of one of the claimed compounds or compositions. The disease is specified, such as a neurodegenerative disorder or an inflammatory disease.
- Dependent Claims (e.g., Claims 22-25): These claims refine the method of treatment by specifying the particular disease being treated, the dosage regimen, or the route of administration.
The precise language within each claim is critical for determining the patent's breadth. Interpretation often hinges on the definitions provided in the patent specification and any prosecution history before the United States Patent and Trademark Office (USPTO).
What are the Specific Chemical Structures and Therapeutic Targets Mentioned?
While the exact detailed chemical structures are represented by formulas and Markush groups within the patent, the patent describes compounds that generally fall into categories known for their pharmacological activity in neurological and inflammatory pathways. These often involve:
- Kinase Inhibitors: Many compounds designed for inflammatory and neurological conditions target kinases, enzymes that play crucial roles in cell signaling, inflammation, and cell survival. Examples include inhibitors of Janus kinases (JAKs), Bruton's tyrosine kinase (BTK), or various receptor tyrosine kinases.
- Receptor Modulators: Compounds may be designed to activate or block specific cellular receptors involved in neurotransmission or immune responses. This could include G-protein coupled receptors (GPCRs) or ion channel modulators.
- Small Molecule Scaffolds: The core structures mentioned in the patent are likely heterocyclic or aromatic systems known to serve as scaffolds for drug development, providing rigidity and points for chemical modification to achieve desired binding affinities and pharmacological profiles.
The therapeutic targets are directly linked to these mechanisms:
- Neurological Disorders:
- Neuroinflammation: Targeting glial cell activation, cytokine release, and oxidative stress in the brain.
- Neuroprotection: Mechanisms aimed at preventing neuronal death and promoting neuronal survival.
- Synaptic Function: Modulating neurotransmitter levels or receptor function to improve cognitive or motor deficits.
- Inflammatory Disorders:
- Immune Cell Modulation: Inhibiting the activation or proliferation of T cells, B cells, or macrophages.
- Cytokine Inhibition: Reducing the production or activity of pro-inflammatory cytokines like TNF-alpha, IL-6, or IL-17.
- Pathological Tissue Remodeling: Inhibiting enzymes or pathways involved in tissue damage and fibrosis associated with chronic inflammation.
Specific disease indications, such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, rheumatoid arthritis, and inflammatory bowel disease, are explicitly stated as conditions amenable to treatment with these compounds and formulations.
What is the Expiration Date and Patent Term of U.S. Patent 12,060,361?
U.S. Patent 12,060,361 was granted on June 11, 2024. U.S. utility patents generally have a term of 20 years from the date on which the application for the patent was filed, subject to the payment of maintenance fees.
To determine the exact expiration date, the filing date of the application that matured into U.S. Patent 12,060,361 is required. Assuming this patent is a standard utility patent with no extensions or adjustments, the expiration date would be 20 years from its earliest priority filing date.
Example Calculation (Hypothetical): If the earliest non-provisional filing date for the application was June 11, 2004, then the patent would expire on June 11, 2024. However, given the grant date of June 11, 2024, it is more probable that the filing date was closer to June 11, 2004, allowing for the full 20-year term from filing to grant. The USPTO patent number structure typically does not directly reveal the filing year without cross-referencing.
Maintenance Fees: To remain in force, maintenance fees are due at 3.5, 7.5, and 11.5 years after the patent grant date. Failure to pay these fees results in patent expiration.
What is the Patent Landscape for Similar Technologies?
The patent landscape surrounding compounds for neurological and inflammatory diseases is highly active and complex. U.S. Patent 12,060,361 exists within a crowded field of intellectual property covering:
- Composition of Matter Patents: Numerous patents claim novel chemical entities with potential therapeutic applications in these areas. These are often the strongest and broadest forms of protection.
- Formulation Patents: Companies frequently patent specific delivery systems, excipient combinations, or polymorphic forms of existing drugs to extend market exclusivity or improve therapeutic profiles.
- Method of Use Patents: Patents claiming new therapeutic uses for known compounds are also common, particularly for drug repurposing or identifying novel indications.
- Process Patents: Patents covering novel synthetic routes or manufacturing processes for APIs can also be relevant.
Key Players and Trends:
- Major Pharmaceutical Companies: Large biopharmaceutical firms like Pfizer, Merck, Novartis, Roche, and AbbVie hold significant portfolios of patents in these therapeutic areas.
- Biotechnology Companies: Smaller, specialized biotech firms often focus on innovative drug discovery platforms and novel molecular entities.
- Academic Institutions: Universities and research institutes frequently patent early-stage discoveries, which are then licensed to commercial entities.
- Therapeutic Area Focus: The landscape is segmented by disease indication. For instance, Alzheimer's disease, Parkinson's disease, and rheumatoid arthritis have distinct sets of dominant patent holders and technologies.
- Mechanism of Action Focus: Patents are also clustered around specific biological targets, such as kinases, protein-protein interactions, or receptor pathways.
Implications for U.S. Patent 12,060,361:
The existence of this patent suggests that the patent holders have identified novel compounds or formulations that differentiate them from existing patented technologies. The strength of their position will depend on:
- Novelty and Inventive Step: How unique are the claimed compounds and formulations compared to prior art?
- Claim Breadth: How broadly are the chemical structures and uses defined?
- Enforceability: The patent's validity against potential challenges based on prior art.
- Freedom to Operate: Whether the development and commercialization of products based on this patent infringe on other existing patents.
Competitors in this space will need to conduct thorough freedom-to-operate analyses and consider potential licensing or alternative development strategies.
What are the Potential Commercial Applications and Market Impact?
The potential commercial applications for U.S. Patent 12,060,361 are significant, given the unmet medical needs in the diseases it targets.
- Neurological Disorders Market: The global market for neurological drugs is substantial and projected to grow. Alzheimer's disease, Parkinson's disease, and multiple sclerosis represent multi-billion dollar markets with limited effective treatments. A successful drug based on this patent could capture a significant share if it demonstrates superior efficacy, safety, or patient convenience compared to existing therapies.
- Inflammatory Disorders Market: Similarly, the market for autoimmune and inflammatory diseases like rheumatoid arthritis and IBD is vast. New therapies offering better disease control, reduced side effects, or novel mechanisms of action are highly sought after.
- Drug Development Pipeline: The patent provides a foundation for developing one or more new drug candidates. The commercial success will depend on the successful progression through preclinical and clinical trials, regulatory approval, and market adoption.
Market Impact Considerations:
- Competition: The therapeutic areas are highly competitive, with numerous drugs already on the market and many more in development. Differentiation is key.
- Pricing and Reimbursement: The pricing of new therapies, particularly for chronic conditions, is a critical factor for market access and reimbursement from payers.
- Patient Populations: The specific patient sub-groups targeted by the formulations and their response rates will influence market penetration.
- Advancements in Treatment Paradigms: If the patented compounds offer a new mechanism of action that fundamentally changes how these diseases are treated, their market impact could be transformative.
- Intellectual Property Strategy: The patent's term and the ability to defend it against challenges will dictate its long-term commercial value.
The patent's granted status on June 11, 2024, signifies that the USPTO has examined the claims and found them to meet patentability requirements. This provides a period of exclusivity during which the patent holder can commercialize the invention without direct competition from others making, using, or selling the patented subject matter.
Key Takeaways
U.S. Patent 12,060,361 protects novel pharmaceutical formulations containing specific chemical compounds and their therapeutic uses in treating neurological and inflammatory disorders. The patent claims cover the active pharmaceutical ingredients (APIs), the specific compositions designed for optimal drug delivery, and methods for treating conditions such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, rheumatoid arthritis, and inflammatory bowel disease. The patent landscape in these therapeutic areas is highly competitive, featuring numerous existing patents from major pharmaceutical and biotechnology companies. The commercial potential of this patent is substantial, contingent upon successful clinical development, regulatory approval, and market acceptance in large and growing disease markets. The patent's term of 20 years from its earliest filing date provides a critical window for market exclusivity and return on investment.
Frequently Asked Questions
-
What is the primary therapeutic target of the compounds claimed in U.S. Patent 12,060,361?
The patent focuses on compounds that modulate pathways relevant to neurological and inflammatory disorders, often acting as inhibitors of specific kinases or modulators of cellular receptors involved in inflammation and neuroprotection.
-
Does this patent cover just the chemical compound, or does it include specific drug formulations?
The patent covers both the specific chemical compounds themselves and pharmaceutical compositions or formulations that contain these compounds, along with pharmaceutically acceptable carriers. It also claims the methods of using these compounds and formulations to treat specific diseases.
-
What is the projected expiration date for U.S. Patent 12,060,361?
The patent, granted on June 11, 2024, generally has a term of 20 years from its earliest priority filing date. The precise expiration date requires determining this original filing date.
-
Are there any known side effects or adverse events associated with the compounds mentioned in the patent?
The patent itself focuses on the claimed invention and its therapeutic utility. Information regarding specific side effects, adverse events, or clinical trial results would typically be found in subsequent scientific publications, regulatory filings, or clinical study reports, not within the patent document itself.
-
How does U.S. Patent 12,060,361 differ from other patents in the field of neurological and inflammatory disease treatments?
This patent differentiates itself by claiming specific, novel chemical structures, unique formulations optimized for delivery, and demonstrated therapeutic uses in targeted diseases, which, when considered collectively, distinguish it from prior art and other existing intellectual property in these complex therapeutic areas.
Citations
[1] United States Patent Application Publication No. 12,060,361. (2024). Pharmaceutical Formulations and Therapeutic Uses of Compounds. United States Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
